SanBio
Business Services · Japan · 11-50 Employees
View Company Info for Free
Overview
Headquarters
8-1 Chuo-ku, Akashichou, Tokyo, 104-0044...Phone Number
+81 362643481Website
www.sanbio.comRevenue
$28.6 MillionStock Symbol
4592Industry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About SanBio
SanBio Co., Ltd. specializes in the development, manufacturing, and sales of regenerative cell therapies targeting central nervous system diseases such as stroke and traumatic brain injury. The company aims to create groundbreaking treatments for chronic stroke and traumatic brain injury. With a focus on allogeneic stem cell transplantation, SanBio seeks to reduce costs and improve accessibility to its therapies for a larger patient population. Their development team, led by experts in regenerative medicine, is dedicated to advancing innovative medical solutions.Explore more
SanBio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SanBio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at SanBio
Click to see if SanBio had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check out if SanBio is spiking on competitors!
Check if SanBio has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once SanBio has new funding data
SanBio, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on SanBio recently announced quarterly report
Product Launch: Get notified when SanBio launches new products
Recommended Actions
Reach out to Masked Content who joined SanBio as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
SanBio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
SanBio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about SanBio.
SanBio financials insights
Gather financial insights about SanBio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$1M
SanBio Tech Stack
A closer look at the technologies used by SanBio
See more technologies
SanBio News & Media
SanBio Company Limited (SNBOY) Q2 2026 Earnings Call Prepared Remarks Transcript
SanBio Company Limited (OTC:SNBOY) Q2 2026 Earnings Call September 18, 2025 3:00 AM EDTCompany ParticipantsKeita Mori - Co-Founder, President, Executive...SanBio Obtains Marketing Approval for “AKUUGO® Suspension for Intracranial Implantation” (INN: Vandefitemcel) as a Therapeutic Agent for Improving Chronic Motor Paralysis From Traumatic Brain Injury (TBI)
TOKYO--(BUSINESS WIRE)--SanBio Co., Ltd. (TOKYO:4592) (head office: Tokyo, representative director & CEO: Keita Mori) hereby announces that today on July 31 2024, it obtained conditional and time-limited marketing approval for the human somatic stem cell-processed product “AKUUGO® suspension for intracranial implantation” (INN: vandefitemcel; hereafter, “AKUUGO®”) in Japan, for the indication of improving chronic motor paralysis resulting from traumatic brain injury. Traumatic brain injurySB623 Demonstrated Sustained Improvement in Motor Impairment up to 48 Weeks and Associated with Improvement in Function and Activities of Daily Living in Patients with Chronic Traumatic Brain Injury
TOKYO & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--The SanBio Group today announced that SB623 met the primary endpoint in the final, one-year analysis of the Phase 2 STEMTRA trial in patients.SanBio: Notice Regarding Completion of Approval Filing for Japan SB623 Chronic TBI Program
TOKYO & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--SanBio completed the application filing with Japan’s MHLW for manufacture and marketing approval as a regenerative medicine product.
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding SanBio
Sign Up For FreeTo access detailed company insights
SanBio Co., Ltd. specializes in the development, manufacturing, and sales of regenerative cell therapies targeting central nervous system diseases such as stroke and traumatic brain injury. The company aims to create groundbreaking treatments for chronic stroke and traumatic brain injury. With a focus on allogeneic stem cell transplantation, SanBio... Read More
